Showing results (371-380 of 398) with videos related to

Sort By:
Pageof 40
Nuclear Medicine and Biology|January 11, 2007
Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analoguesElisa García Garayoa, Dominique Rüegg, Peter Bläuenstein, et al.
American Journal of Hypertension|May 26, 1999
Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjectsJ D Blumenfeld, J E Sealey, S J Mann, et al.
The American Journal of Physiology|November 14, 1997
Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic miceC R Aversa, S Oparil, J Caro, et al.
Nuclear Medicine and Biology|January 12, 2002
PET imaging of dopamine transporters in the human brain using [(11)C]-beta-CPPIT, a cocaine derivative lacking the 2 beta-ester functionRoland D Schönbächler, Pascale M Gucker, Michele Arigoni, et al.
The Journal of Clinical Endocrinology and Metabolism|September 11, 2008
Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinionGilbert P August, Sonia Caprio, Ilene Fennoy, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
American Journal of Hypertension|September 12, 2000
Factors affecting blood pressure responses to diet: the Vanguard studyL M Resnick, S Oparil, A Chait, et al.
The American Journal of Clinical Nutrition|December 1, 1996
Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared dietD C Hatton, R B Haynes, S Oparil, et al.
Neuropharmacology|September 24, 2004
A-186253, a specific antagonist of the alpha 4 beta 2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptorsValérie Itier, Roland Schönbächler, Eliane Tribollet, et al.
Pageof 40